Matthew B. McQueen
University of Colorado Boulder
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matthew B. McQueen.
Nature Genetics | 2007
Lars Bertram; Matthew B. McQueen; Kristina Mullin; Deborah Blacker; Rudolph E. Tanzi
The past decade has witnessed hundreds of reports declaring or refuting genetic association with putative Alzheimer disease susceptibility genes. This wealth of information has become increasingly difficult to follow, much less interpret. We have created a publicly available, continuously updated database that comprehensively catalogs all genetic association studies in the field of Alzheimer disease (http://www.alzgene.org). We performed systematic meta-analyses for each polymorphism with available genotype data in at least three case-control samples. In addition to identifying the ε4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11–1.38 for risk alleles and 0.92–0.67 for protective alleles). Our database provides a powerful tool for deciphering the genetics of Alzheimer disease, and it serves as a potential model for tracking the most viable gene candidates in other genetically complex diseases.
Molecular Psychiatry | 2008
Pamela Sklar; Jordan W. Smoller; Jinbo Fan; Manuel A. Ferreira; Roy H. Perlis; Vishwajit L. Nimgaonkar; Matthew B. McQueen; Stephen V. Faraone; Andrew Kirby; P. I. W. de Bakker; Matthew N. Ogdie; Michael E. Thase; Gary S. Sachs; Katherine E. O. Todd-Brown; Stacey Gabriel; Carrie Sougnez; Casey Gates; Brendan Blumenstiel; Matthew DeFelice; Kristin Ardlie; J Franklin; Walter J. Muir; Kevin A. McGhee; Donald J. MacIntyre; Alan W. McLean; M VanBeck; Andrew McQuillin; Nick Bass; Matthew Robinson; Jacob Lawrence
We performed a genome-wide association scan in 1461 patients with bipolar (BP) 1 disorder, 2008 controls drawn from the Systematic Treatment Enhancement Program for Bipolar Disorder and the University College London sample collections with successful genotyping for 372 193 single nucleotide polymorphisms (SNPs). Our strongest single SNP results are found in myosin5B (MYO5B; P=1.66 × 10−7) and tetraspanin-8 (TSPAN8; P=6.11 × 10−7). Haplotype analysis further supported single SNP results highlighting MYO5B, TSPAN8 and the epidermal growth factor receptor (MYO5B; P=2.04 × 10−8, TSPAN8; P=7.57 × 10−7 and EGFR; P=8.36 × 10−8). For replication, we genotyped 304 SNPs in family-based NIMH samples (n=409 trios) and University of Edinburgh case–control samples (n=365 cases, 351 controls) that did not provide independent replication after correction for multiple testing. A comparison of our strongest associations with the genome-wide scan of 1868 patients with BP disorder and 2938 controls who completed the scan as part of the Wellcome Trust Case–Control Consortium indicates concordant signals for SNPs within the voltage-dependent calcium channel, L-type, alpha 1C subunit (CACNA1C) gene. Given the heritability of BP disorder, the lack of agreement between studies emphasizes that susceptibility alleles are likely to be modest in effect size and require even larger samples for detection.
PLOS Genetics | 2012
Christina M. Lill; Johannes T. Roehr; Matthew B. McQueen; Fotini K. Kavvoura; Sachin Bagade; Brit-Maren M. Schjeide; Leif Schjeide; Esther Meissner; Ute Zauft; Nicole C. Allen; Tian-Jing Liu; Marcel Schilling; Kari J. Anderson; Gary W. Beecham; Daniela Berg; Joanna M. Biernacka; Alexis Brice; Anita L. DeStefano; Chuong B. Do; Nicholas Eriksson; Stewart A. Factor; Matthew J. Farrer; Tatiana Foroud; Thomas Gasser; Taye H. Hamza; John Hardy; Peter Heutink; Erin M. Hill-Burns; Christine Klein; Jeanne C. Latourelle
More than 800 published genetic association studies have implicated dozens of potential risk loci in Parkinsons disease (PD). To facilitate the interpretation of these findings, we have created a dedicated online resource, PDGene, that comprehensively collects and meta-analyzes all published studies in the field. A systematic literature screen of ∼27,000 articles yielded 828 eligible articles from which relevant data were extracted. In addition, individual-level data from three publicly available genome-wide association studies (GWAS) were obtained and subjected to genotype imputation and analysis. Overall, we performed meta-analyses on more than seven million polymorphisms originating either from GWAS datasets and/or from smaller scale PD association studies. Meta-analyses on 147 SNPs were supplemented by unpublished GWAS data from up to 16,452 PD cases and 48,810 controls. Eleven loci showed genome-wide significant (P<5×10−8) association with disease risk: BST1, CCDC62/HIP1R, DGKQ/GAK, GBA, LRRK2, MAPT, MCCC1/LAMP3, PARK16, SNCA, STK39, and SYT11/RAB25. In addition, we identified novel evidence for genome-wide significant association with a polymorphism in ITGA8 (rs7077361, OR 0.88, P = 1.3×10−8). All meta-analysis results are freely available on a dedicated online database (www.pdgene.org), which is cross-linked with a customized track on the UCSC Genome Browser. Our study provides an exhaustive and up-to-date summary of the status of PD genetics research that can be readily scaled to include the results of future large-scale genetics projects, including next-generation sequencing studies.
Brain Research | 1999
Ruth E. Grahn; Matthew J. Will; Sayamwong E. Hammack; Sharmin Maswood; Matthew B. McQueen; Linda R. Watkins; S.F. Maier
The dorsal raphe nucleus (DRN) and its serotonergic terminal regions have been suggested to be part of the neural substrate by which exposure to uncontrollable stressors produces poor escape responding and enhanced conditioned fear expression. Such stressor exposure is thought to selectively activate DRN serotonergic neurons in such a way as to render them transiently sensitized to further input. As a result of this sensitized state, behavioral testing procedures are thought to cause excess serotonergic activity in brain regions that control these behaviors. The present studies were conducted to investigate activity in the DRN following exposure to escapable and yoked, inescapable tailshock. Neural activity was characterized using immunohistochemistry to detect the immediate early gene product Fos in serotonin-immunoreactive cells in the DRN. Inescapable tailshock led to greater serotonergic neural activity than did escapable tailshock, supporting the hypothesis that uncontrollable stressors preferentially activate serotonergic neurons in the DRN.
American Journal of Human Genetics | 2005
Matthew B. McQueen; Bernie Devlin; Stephen V. Faraone; Vishwajit L. Nimgaonkar; Pamela Sklar; Jordan W. Smoller; Rami Abou Jamra; Margot Albus; Silviu-Alin Bacanu; Miron Baron; Thomas B. Barrett; Wade H. Berrettini; Deborah Blacker; William Byerley; Sven Cichon; Willam Coryell; Nicholas John Craddock; Mark J. Daly; J. Raymond DePaulo; Howard J. Edenberg; Tatiana Foroud; Michael Gill; T. Conrad Gilliam; Marian Lindsay Hamshere; Ian Richard Jones; Lisa Jones; S H Juo; John R. Kelsoe; David Lambert; Christoph Lange
Several independent studies and meta-analyses aimed at identifying genomic regions linked to bipolar disorder (BP) have failed to find clear and consistent evidence of linkage regions. Our hypothesis is that combining the original genotype data provides benefits of increased power and control over sources of heterogeneity that outweigh the difficulty and potential pitfalls of the implementation. We conducted a combined analysis using the original genotype data from 11 BP genomewide linkage scans comprising 5,179 individuals from 1,067 families. Heterogeneity among studies was minimized in our analyses by using uniform methods of analysis and a common, standardized marker map and was assessed using novel methods developed for meta-analysis of genome scans. To date, this collaboration is the largest and most comprehensive analysis of linkage samples involving a psychiatric disorder. We demonstrate that combining original genome-scan data is a powerful approach for the elucidation of linkage regions underlying complex disease. Our results establish genomewide significant linkage to BP on chromosomes 6q and 8q, which provides solid information to guide future gene-finding efforts that rely on fine-mapping and association approaches.
Nature Genetics | 2005
Kristel Van Steen; Matthew B. McQueen; Alan Herbert; Benjamin A. Raby; Helen N. Lyon; Dawn L. DeMeo; Amy Murphy; Jessica Su; Soma Datta; Carsten Rosenow; Michael F. Christman; Edwin K. Silverman; Nan M. Laird; Scott T. Weiss; Christoph Lange
The Human Genome Project and its spin-offs are making it increasingly feasible to determine the genetic basis of complex traits using genome-wide association studies. The statistical challenge of analyzing such studies stems from the severe multiple-comparison problem resulting from the analysis of thousands of SNPs. Our methodology for genome-wide family-based association studies, using single SNPs or haplotypes, can identify associations that achieve genome-wide significance. In relation to developing guidelines for our screening tools, we determined lower bounds for the estimated power to detect the gene underlying the disease-susceptibility locus, which hold regardless of the linkage disequilibrium structure present in the data. We also assessed the power of our approach in the presence of multiple disease-susceptibility loci. Our screening tools accommodate genomic control and use the concept of haplotype-tagging SNPs. Our methods use the entire sample and do not require separate screening and validation samples to establish genome-wide significance, as population-based designs do.
Biological Psychiatry | 2008
Isabel R. Schlaepfer; Nicole R. Hoft; Allan C. Collins; Robin P. Corley; John K. Hewitt; Christian J. Hopfer; Jeffrey M. Lessem; Matthew B. McQueen; Soo Hyun Rhee; Marissa A. Ehringer
BACKGROUND One potential site of convergence of the nicotine and alcohol actions is the family of the neuronal nicotinic acetylcholine receptors. Our study examines the genetic association between variations in the genomic region containing the CHRNA5, A3, and B4 gene cluster (A5A3B4) and several phenotypes of alcohol and tobacco use in an ethnically diverse young adult sample. Significant results were then replicated in a separate adult population-representative sample. METHODS In a selected sample, nine single nucleotide polymorphisms (SNPs) were tested for association with various nicotine and alcohol phenotypes, including age of initiation and measures of frequency, quantity, and subjective responses to the substances. Analysis was conducted with the statistical genetics program WHAP in the full sample (1075 subjects) including ethnicities as covariates and within each ethnic group sub-sample. Replication of the significant results in a separate population-based sample was carried out with the PBAT statistical genetics program. RESULTS Two linked SNPs (rs8023462 and rs1948) located in a conserved region of the A5A3B4 gene cluster significantly predicted early age of initiation for tobacco with a hazard ratio (HR) of 1.35 (95% confidence interval [CI]1.08-1.70) for the CC genotype of rs8023462 and a HR of 1.29 (95% CI 1.01-1.63) for the TT genotype of rs1948 [corrected]. These findings were then replicated in a separate population-representative sample, showing rs1948 and rs8023462 to be associated with age of initiation for both tobacco and alcohol use (p < .01 and p < .001). CONCLUSIONS Variations in A5A3B4 genes might influence behaviors that promote early age of experimentation with drugs.
Epidemiology | 2011
Melinda C. Power; Jennifer Weuve; Joshua J. Gagne; Matthew B. McQueen; Anand Viswanathan; Deborah Blacker
Background: Many epidemiologic studies have considered the association between blood pressure (BP) and Alzheimer disease, yet the relationship remains poorly understood. Methods: In parallel with work on the AlzRisk online database (www.alzrisk.org), we conducted a systematic review to identify all epidemiologic studies meeting prespecified criteria reporting on the association between hypertension, systolic BP, or diastolic BP and incident Alzheimer disease. When possible, we computed summary measures using random-effects models and explored potential heterogeneity related to age at BP assessment. Results: Eighteen studies reporting on 19 populations met the eligibility criteria. We computed summary relative risks (RR&Sgr;) for 3 measures of BP: hypertension (RR&Sgr; = 0.97 [95% confidence interval = 0.80–1.16]); a 10-mm Hg increase in systolic BP (RR&Sgr; = 0.95 [0.91–1.00]); and a 10-mm Hg increase in diastolic BP (RR&Sgr; = 0.94 [0.85–1.04]). We were unable to compute summary estimates for the association between categories of systolic or diastolic BP and Alzheimer disease; however, there did not appear to be a consistent pattern across studies. After stratifying on age at BP assessment, we found a suggestion of an inverse association between late-life hypertension and Alzheimer disease and a suggestion of an adverse association between midlife diastolic hypertension and Alzheimer disease. Conclusions: Based on existing epidemiologic research, we cannot determine whether there is a causal association between BP and Alzheimer disease. Selection bias and reverse causation may account for the suggested inverse association between late-life hypertension on Alzheimer disease, but, given the expected direction of these biases, they are less likely to account for the suggestion that midlife hypertension increases risk. We advocate continuing systematic review; the AlzRisk database entry on this topic (www.alzrisk.org), which was completed in parallel with this work, will be updated as new studies are published.
Neuropsychopharmacology | 2009
Nicole R. Hoft; Robin P. Corley; Matthew B. McQueen; Isabel R. Schlaepfer; David Huizinga; Marissa A. Ehringer
Neuronal nicotinic acetylcholine receptors are activated by both endogenous acetylcholine and exogenous nicotine, making sequence variations in these receptors likely candidates for association with tobacco phenotypes. Previous studies have found evidence for significant association between single nucleotide polymorphisms (SNPs) in the genomic region containing the CHRNA6 and CHRNB3 genes and tobacco behaviors. In this study, we provide support for an association between these genes and tobacco dependence in the National Youth Survey Family Study wave 10, a nationally representative sample of households. Eight SNPs in the CHRNA6 and CHRNB3 genomic region were genotyped in 1051 subjects, approximately half of whom are members of sibling pairs. Genetic association with DSM-IV dependence was assessed using a family-based approach as implemented in the statistical package PBAT. Individual SNPs were tested for association with quit attempts and overall dependence. Variation in CHRNA6 was found to be associated with tobacco dependence (p=0.007 in Caucasians). SNPs in CHRNB3 were found to be associated with the number of quit attempts (p=0.0024). Together these results further implicate the region downstream of CHRNA6 and the region upstream of CHRNB3 in risk of nicotine dependence.
American Journal of Human Genetics | 2007
Iuliana Ionita-Laza; Matthew B. McQueen; Nan M. Laird; Christoph Lange
For genomewide association (GWA) studies in family-based designs, we propose a novel two-stage strategy that weighs the association P values with the use of independently estimated weights. The association information contained in the family sample is partitioned into two orthogonal components--namely, the between-family information and the within-family information. The between-family component is used in the first (i.e., screening) stage to obtain a relative ranking of all the markers. The within-family component is used in the second (i.e., testing) stage in the framework of the standard family-based association test, and the resulting P values are weighted using the estimated marker ranking from the screening step. The approach is appealing, in that it ensures that all the markers are tested in the testing step and, at the same time, also uses information from the screening step. Through simulation studies, we show that testing all the markers is more powerful than testing only the most promising ones from the screening step, which was the method suggested by Van Steen et al. A comparison with a population-based approach shows that the approach achieves comparable power. In the presence of a reasonable level of population stratification, our approach is only slightly affected in terms of power and, since it is a family-based method, is completely robust to spurious effects. An application to a 100K scan in the Framingham Heart Study illustrates the practical advantages of our approach. The proposed method is of general applicability; it extends to any setting in which prior, independent ranking of hypotheses is available.